The Center for Childhood Infections and Vaccines (CCIV) is addressing major childhood infectious diseases through innovative research into microbial pathogenesis, immune responses in children, and the development of new vaccines and therapeutics.
The center has five integrative focus areas that are designed to build new collaborations, which will lead to sustainable research programs, new grant opportunities and important discoveries. You can learn more about these programs below.
Click "Newsletters & News" in the left menu to learn about the recent happenings of the center.
The full CCIV events calendar is here.
The third annual CCIV Symposium will be on October 17. Learn more here, including poster session information and trainee lunches with the keynote speakers.
Monday Morning Seminar Series
CCIV Labs come together on Monday mornings at 9 am in ECC 302. Join the discussion and coffee. See current schedule here.
- October 22: Justin O'Neal (Suthar Lab)
- October 29: Xuemin Chen (E. Anderson Lab)
- November 5: Christina Gavegnano (Schinazi Lab)
- November 12: Katherine Bricker (Chahroudi Lab)
- November 19: Deborah Block (Cranmer Lab)
- November 26: Cancelled for Thanksgiving
If you would like to use the CCIV logo on your poster, contact Karen Kennedy.
Atlanta is a leading global center of infectious diseases research, including strengths at Emory University and the Centers for Disease Control and Preventions (CDC). Investigators from a number of additional institutions add to strengths in this area, including Georgia Tech, Morehouse School of Medicine, The University of Georgia, and Medical College of Georgia. Children’s Healthcare of Atlanta will build on these strengths through the CCIV, working with partner institutions in a new enterprise that focuses on microbial pathogenesis, immune responses in children, and the development of new vaccines and therapeutics.
To achieve the overarching goal of impacting child health on a global scale, CCIV will:
- Enhance understanding of infectious diseases, basic immunologic processes, and the development of vaccines and treatments against childhood pathogens.
- Build new collaborations and interdisciplinary projects leading to new extramural funding.
- Develop a program and critical mass of investigators focused on infectious diseases and emerging global health issues. We will integrate efforts within the CCIV with those at the Emory Vaccine Center, Emory Transplant Center, the Carter Center, the Emory Global Health Institute, and CDC initiatives. Participation in CCIV initiatives is open to investigators from these and other research institutions throughout the state of Georgia.
This program includes laboratories focused on basic biology and immunology of the following pathogens:
- Measles virus
- Respiratory syncytial virus (RSV)
- Viral and Bacterial Diarrheal Pathogens
- Structural basis of host-pathogen interactions
The innate immunity program focuses on basic aspects of the immune response to foreign antigens, including the early responses that change the adaptive immune responses. Novel adjuvants (stimulants of the innate response that can enhance vaccine efficacy) are one area of focus of this program.
Vaccine responses in young infants are complicated by an immature immune system and sometimes by the presence of maternal antibody. This program focuses on unique aspects of immunity in the developing fetus and the newborn infant, with the goal of enhancing the efficacy of vaccines given to infants.
The Global Infectious Diseases Program is focused on clinical research and interventions for pathogens that are major causes of childhood mortality in the developing world. Current areas of research by CCIV investigators in this Program include epidemiology and treatment for malaria and rotavirus vaccine efficacy in the developing world.
This program spans the spectrum of the vaccine development process, from the design and testing of new vaccines in the lab to the performance of human clinical trials. The program currently is focusing on vaccines against malaria, rhinovirus, respiratory syncytial virus, HIV/AIDS, Ebola, Zika, and influenza.